Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Block Inc (XYZ) Price & Performance

10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Block Inc — how do they compare? 10X Genomics Inc trades at $57.6 (market cap $7.61B), while Block Inc trades at $78.45 (market cap $47.50B). The key difference: Block Inc is far larger — about 6.2× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals.

TXGXYZ
Market Cap
$7.61B$47.50B
Sector
HealthTechnology
52-Week High
$58.57$84.64
52-Week Low
$11.34$49.04
Enterprise Value
$7.14B$42.41B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.

Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.

Block Inc

XYZ trades at $77.97, down 1.28% on the day, with strong analyst support (75% buy ratings) and a $99.47 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, including Q2 EPS of $1.02 beating $0.871 estimates. Revenue reached $24.19B in 2025, though net margins remain thin at 1.43%. Recent news highlights Square's expanded credit card features and AI integration driving operational efficiency.

Outlook remains positive with raised 2026 guidance and 25% gross profit growth, though high P/E of 141.2 signals premium valuation. Key risks include competitive fintech pressure and execution on AI initiatives. Institutional buying and strong Cash App performance support upside potential toward price targets.

Returns comparison

Trailing returns across standard periods

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About Block Inc

Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom

Read more on XYZ